stockrowSpruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Revenue
- −75.9%
- EPS
- −90.9%
- Free cash flow
- −152.1%
- Total debt
- +427.2%
Quarter to June 2026, against a year earlier
Follow SPRB
Alert me
Spruce Biosciences, Inc. (SPRB) Return on invested capital
Spruce Biosciences, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −95.1% (fiscal 2021) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 95.12 |
| FY2021 | −95.1% | (95.12) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PDSB PDS Biotechnology Corporation compare | 0.00% |
| CUE Cue Biopharma, Inc. compare | 0.00% |
| MENS Jyong Biotech Ltd. compare | 0.00% |
| CHRS Coherus Oncology, Inc. compare | 0.00% |
| YARW Yarrow Bioscience, Inc compare | 0.00% |
| MOLN Molecular Partners AG Sponsored ADR compare | 0.00% |
| SPRB Spruce Biosciences, Inc. | 0.00% |
| CMPX Compass Therapeutics, Inc. compare | 0.00% |
| TARA Protara Therapeutics, Inc. compare | −255.1% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)